Health Technology
SAMSUNG BIOLOGICS Co., Ltd.
In the news
- Samsung Biologics to invest $1.5bn for new pharmaceutical plant Aug 11, 2020
- Samsung Biologics snags $1.5bn in orders on pandemic rush Jun 29, 2020
- Toyota AGM, Macao casino regulator, Vietnam-EU trade deal Jun 7, 2020
- South Korea seeks arrest of Samsung heir in succession probe Jun 4, 2020
- Kakao tops Hyundai in market cap as pandemic shakes up Korea Inc. May 25, 2020 See more articles on SAMSUNG BIOLOGICS Co., Ltd.
Business Summary
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Financial Highlights
| Dec 2021 | KRW | USD |
| Revenue | 1,568.00B | 1,369.24M |
| Gross Profit | 784,969.49M | 685.46M |
| Operating income | 537,309.40M | 469.20M |
| Income before tax | 547,429.45M | 478.03M |
| Net income | 393,589.46M | 343.69M |
| EBITDA | 699,098.05M | 610.48M |
| Diluted EPS | 5,886.12 | 5.14 |
| Dividends Per Share | 0 | 0 |
| Total Assets | 7,970.01B | 6,704.53M |
| Total liabilities | 2,978.90B | 2,505.91M |
| Total equity | 4,991.10B | 4,198.61M |
| Operating cash flow | 454,596.21M | 396.97M |
| Currency in KRW | Currency in USD |
Historical Data
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | |
| Revenue | 464,629.33M | 535,805.80M | 701,591.85M | 1,164.77B | 1,568.00B |
| Gross Profit | 122,304.94M | 130,544.55M | 230,536.76M | 469,262.42M | 784,969.49M |
| Operating income | 65,979.40M | 55,678.74M | 92,084.47M | 293,299.68M | 537,309.40M |
| Income before tax | -115,994.75M | 302,975.83M | 82,495.19M | 283,759.85M | 547,429.45M |
| Net income | -96,972.11M | 224,109.19M | 202,904.09M | 240,974.79M | 393,589.46M |
| EBITDA | 135,905.62M | 147,129.29M | 224,627.48M | 436,474.55M | 699,098.05M |
| Diluted EPS | -1,450.60 | 3,351.42 | 3,034.42 | 3,603.77 | 5,886.12 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 7,183.09B | 5,980.40B | 5,911.62B | 6,424.20B | 7,970.01B |
| Total liabilities | 3,206.64B | 1,824.94B | 1,557.17B | 1,825.41B | 2,978.90B |
| Total equity | 3,976.45B | 4,155.46B | 4,354.45B | 4,598.78B | 4,991.10B |
| Operating cash flow | 149,816.32M | 36,787.30M | 10,153.61M | 202,090.02M | 454,596.21M |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | |
| Revenue | 410.99M | 486.86M | 601.61M | 987.19M | 1,369.24M |
| Gross Profit | 108.18M | 118.62M | 197.68M | 397.71M | 685.46M |
| Operating income | 58.36M | 50.59M | 78.96M | 248.58M | 469.20M |
| Income before tax | -102.60M | 275.30M | 70.73M | 240.49M | 478.03M |
| Net income | -85.77M | 203.63M | 173.98M | 204.23M | 343.69M |
| EBITDA | 120.21M | 133.69M | 192.61M | 369.92M | 610.48M |
| Diluted EPS | -1.28 | 3.04 | 2.60 | 3.05 | 5.14 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 6,709.72M | 5,359.74M | 5,111.87M | 5,913.83M | 6,704.53M |
| Total liabilities | 2,995.32M | 1,635.54M | 1,346.51M | 1,680.39M | 2,505.91M |
| Total equity | 3,714.39M | 3,724.20M | 3,765.36M | 4,233.43M | 4,198.61M |
| Operating cash flow | 132.52M | 33.42M | 8.70M | 171.27M | 396.97M |
Valuation Measures
| Dec 2021 | |
| PER | 151.80 |
| ROA | 5.46% |
| ROE | 8.20% |
| Operating margin | 34.26% |
| Profit margin | 25.10% |
Key executives
- President, Chief Executive Officer & Director: John Chongbo Rim
- Head-Finance & Vice President: Doyoung Heo
- Managing Director & Head-Process Technology: Yong-Ho An
- Head-Compliance Support: Hyung-Woo Moon
- Executive Vice President: Kyu-Sung Lee
Shareholders
- Samsung C&T Corp. (43.0%)
- Samsung Electronics Co., Ltd. (31.2%)
- National Pension Service of Korea (5.9%)
- Invesco Advisers, Inc. (1.5%)
- BlackRock Fund Advisors (0.5%)
- Samsung Asset Management Co., Ltd. (0.5%)
- The Vanguard Group, Inc. (0.5%)
- Norges Bank Investment Management (0.2%)
- Fidelity Management & Research Co. LLC (0.2%)
- Mirae Asset Global Investments Co., Ltd. (0.2%)
Contact Details
- Website:http://www.samsungbiologics.com
- Address: 300 Songdo Bio Way, Yeonsu-gu, Inchon, 21987, South Korea
- Phone: +82.32.455.3114
Related Companies
- Samsung Biologics America, Inc.
- Samsung BioLogics Co., Ltd. ESOA
- Samsung Romania
Competitors
- Wuxi Biologics (Cayman) Inc.
- Lonza Group AG
- FUJIFILM Holdings Corp
- PanGen Biotech, Inc.
- EirGenix Inc
- Binex Co., Ltd
- Celltrion, Inc.
- Bukwang Pharmaceutical Co., Ltd.
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences, Inc.
- EPIRUS Biopharmaceuticals, Inc.
- Greenwich LifeSciences, Inc.
- Kodiak Sciences, Inc.
- Outlook Therapeutics, Inc.
- PharmAbcine Inc.
- PharmGen Science, Inc.
- Prestige Biologics Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Reyon Pharmaceutical Co., Ltd.
- SCM LIFESCIENCE CO., LTD
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 25 May, 2022Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.